Condition: Breast Adenocarcinoma · Estrogen Receptor Negative · HER2/Neu Negative · Sponsor: NRG Oncology
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Southern Cancer Center PC-Mobile | Mobile, Alabama, United States | — |
| Southern Cancer Center PC-Providence | Mobile, Alabama, United States | — |
| Southern Cancer Center PC-Springhill | Mobile, Alabama, United States | — |
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | — |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | — |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | — |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | — |
| Alaska Regional Hospital | Anchorage, Alaska, United States | — |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | — |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | — |
| Katmai Oncology Group | Anchorage, Alaska, United States | — |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
+ 1284 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.